Pancreatic cancer, the hope of a vaccine to prevent it: the study and the first tests
4 doses of mKras-Vax were administered in 13 weeks, and researchers monitored participants for safety and immune response
- Center-right1
- Agency1
1 agency rewrite / co-publication detected
Summary
4 doses of mKras-Vax were administered in 13 weeks, and researchers monitored participants for safety and immune response through blood tests and follow-up evaluations. In a 16.5-month median follow-up, none of the participants developed a pancreatic tumor or a high-risk pancreatic lesion requiring surgical removal.". "After an average follow-up of 16,5 months, no one has developed pancreatic cancer and some of the precancerous lesions have either reduced or stopped growing.".
Furthermore, The authors noted that "18 of the 20 participants, or 90%, have developed a significant immune response to the vaccine. The study involved 20 people with a hereditary predisposition to pancreatic cancer and a pancreatic anomaly identified by diagnostics for images, which received the vaccine between April 2022 and February 2026. In the arrangements for which follow-up images were available, an exploratory analysis of pancreatic cysts was also conducted: "Those of the 20 participants in the study showed a complete radiographic resolution of small pancreatic cysts, while others 3 presented a partial regression.
In addition, In Phase 1, the first step of clinical trial ister, the vaccine candidate "has stimulated specific T-cell responses for Kras in 90% of participants". Authors call it "the first demonstration on man that a vaccine targeted at Kras can safely generate lasting immune responses, potentially preventing the development of cancer in people at risk" Preventing pancreatic cancer with a vaccine .
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
4 doses of mKras-Vax were administered in 13 weeks, and researchers monitored participants for safety and immune response through blood tests and follow-up evaluations.
reliability low1/2 sourcesIn a 16.5-month median follow-up, none of the participants developed a pancreatic tumor or a high-risk pancreatic lesion requiring surgical removal.".
reliability low1/2 sources"After an average follow-up of 16,5 months, no one has developed pancreatic cancer and some of the precancerous lesions have either reduced or stopped growing.".
reliability low1/2 sourcesThe authors noted that "18 of the 20 participants, or 90%, have developed a significant immune response to the vaccine.
reliability low1/2 sourcesThe study involved 20 people with a hereditary predisposition to pancreatic cancer and a pancreatic anomaly identified by diagnostics for images, which received the vaccine between April 2022 and February 2026.
reliability low1/2 sourcesIn the arrangements for which follow-up images were available, an exploratory analysis of pancreatic cysts was also conducted: "Those of the 20 participants in the study showed a complete radiographic resolution of small pancreatic cysts, while others 3 presented a partial regression.
reliability low1/2 sourcesIn Phase 1, the first step of clinical trial ister, the vaccine candidate "has stimulated specific T-cell responses for Kras in 90% of participants".
reliability low1/2 sources
Reported detailssecondary facts, each attributed to its source
Authors call it "the first demonstration on man that a vaccine targeted at Kras can safely generate lasting immune responses, potentially preventing the development of cancer in people at risk" Preventing pancreatic cancer with a vaccine .
according to Adnkronos
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
